Speaker Profile
Ph.D., CEO, GaudiBio
Biography
Eric Wang, PhD, is CEO and Co-Founder of GaudiBio, a San Francisco–based biotechnology company developing the Gaudium™ system, an AI-enabled platform that integrates human tissue models and genomics to improve how new medicines are discovered and developed.
He has built his career at the intersection of genomics, data, and translational medicine, focused on creating technologies that translate research into real patient impact. Prior to GaudiBio, he helped develop a next-generation DNA sequencing platform at Omniome, later acquired by Pacific Biosciences, and played a key role in building the clinical bioinformatics platform at Ariosa Diagnostics before its acquisition by Roche, where it expanded into cancer diagnostics. Earlier, he contributed to cancer genomics platforms at Veracyte and worked in statistical genetics at Affymetrix, alongside biodefense research at SAIC.
Talk
Accelerating Rare Disease Discovery with Human-Biology Grounded AI Models
Devestating rare diseases remain untreated not for lack of data, but for lack of human-relevant models. GaudiBio integrates patient genomics, human iPSC-derived tissue systems, and AI into a continuously learning discovery engine, translating rare genetic insight into actionable therapeutic hypotheses faster, with greater biological confidence for patients who cannot afford to wait.
AI for Emerging Therapeutics Showcase:
GaudiBio
GaudiBio is unlocking the key to rare and ultra-rare diseases through human biology-grounded tissue models coupled with AI.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 AI for Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies to explore the transformative role of artificial intelligence in accelerating the discovery, development, and optimization of novel therapeutic modalities. From predictive algorithms for drug efficacy to real-time analysis in clinical trials, AI is revolutionizing the way we approach emerging therapies, including RNA-based treatments, gene editing, and personalized medicine. Industry leaders and experts will discuss AI-driven advancements, collaborative frameworks, and the challenges of integrating cutting-edge technologies into therapeutic innovation. Join us for an in-depth look at how AI is shaping the future of breakthrough therapeutics.
